CTOs on the Move

CANTEST

www.cantest.com

 
CANTEST Ltd is a Burnaby, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cantest.com
  • 4606 Canada Way
    Burnaby, BC CAN V5G 1K5
  • Phone: 925.924.6000

Executives

Name Title Contact Details

Similar Companies

Presutti Laboratories

Presutti Laboratories is a Rolling Meadows, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lawrence General Hospital

Drawing inspiration from the pioneering women and community leaders who helped establish the Hospital in 1875, Lawrence General has remained focused throughout its history to serve the community as a private, not-for-profit acute care hospital. The Hospital’s physicians and caregivers offer treatment to all patients, regardless of race, color, creed, or national origin. Every member of the clinical team works to assure the quality and level of care the Hospital provides, supporting community education and research to improve the health of the Merrimack Valley and its citizens.

Nystrom & Associates

Nystrom & Associates Here at Nystrom & Associates, we know that you want to feel confident and excited about life. Were here to help!

VoCare

The Vitals 360® measures 6 key vital signs. It´s like having a portable doctor´s office in the home or anywhere. Heart Rate Blood Pressure Blood Oxygen Saturation ECG Heart Rhythms Temperature Glucose (Not available in the...

Promentis Pharmaceuticals

Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.